Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a global medical device company focused on chronic pain treatment solutions, has announced new employee inducement grants. On August 7, 2024, the company's Compensation Committee granted restricted stock unit awards covering 10,199 shares of Nevro's common stock to four new non-executive employees. These awards, granted under the Nevro Corp. 2023 Inducement Award Plan, are designed to incentivize new hires and will vest over a three-year period, contingent on continued employment. The grants comply with NYSE Listed Company Manual Rule 303A.08, which allows for inducement awards to attract new talent. Nevro also emphasized its practice of posting important investor information on its website.
Nevro Corp. (NYSE: NVRO), un'azienda globale nel settore dei dispositivi medici focalizzata sulle soluzioni per il trattamento del dolore cronico, ha annunciato nuove concessioni agli impiegati. Il 7 agosto 2024, il Comitato per la Retribuzione dell'azienda ha concesso premi in azioni limitate coprendo 10.199 azioni comuni di Nevro a quattro nuovi dipendenti non esecutivi. Questi premi, concessi nell'ambito del Piano di Induzione Nevro Corp. 2023, sono progettati per incentivare le nuove assunzioni e matureranno in un periodo di tre anni, a condizione di un'occupazione continua. Le concessioni sono conformi alla Regola 303A.08 del Manuale delle Aziende Quotata NYSE, che consente premi di induzione per attrarre nuovi talenti. Nevro ha inoltre sottolineato la sua abitudine di pubblicare informazioni importanti per gli investitori sul suo sito web.
Nevro Corp. (NYSE: NVRO), una empresa global de dispositivos médicos centrada en soluciones para el tratamiento del dolor crónico, ha anunciado nuevas concesiones para empleados. El 7 de agosto de 2024, el Comité de Compensación de la empresa otorgó premios de unidades de acciones restringidas que cubren 10,199 acciones ordinarias de Nevro a cuatro nuevos empleados no ejecutivos. Estos premios, otorgados bajo el Plan de Concesiones de Inducción Nevro Corp. 2023, están diseñados para incentivar a los nuevos empleados y se consolidarán durante un período de tres años, condicionado a la continuidad del empleo. Las concesiones cumplen con la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE, que permite los premios de inducción para atraer nuevo talento. Nevro también enfatizó su práctica de publicar información importante para los inversores en su sitio web.
네브로 코프(Nevro Corp.)(NYSE: NVRO)는 만성 통증 치료 솔루션에 초점을 맞춘 글로벌 의료기기 회사로서 새로운 직원 유인 보상을 발표했습니다. 2024년 8월 7일, 회사의 보상위원회는 네브로의 보통주 10,199주에 대한 제한 주식 단위 수여를 네 명의 신규 비임원 직원에게 부여했습니다. 이 보상은 네브로 코프 2023 유인 보상 계획에 따라 제공되며, 신규 채용 인센티브를 위한 것이며, 계속 고용을 조건으로 3년 동안 유예됩니다. 이 보상은 신규 인재를 유치하기 위한 NYSE 상장 기업 매뉴얼 규칙 303A.08을 준수합니다. 네브로는 또한 자사 웹사이트에 중요한 투자자 정보를 게시하는 관행을 강조했습니다.
Nevro Corp. (NYSE: NVRO), une entreprise mondiale de dispositifs médicaux axée sur les solutions de traitement de la douleur chronique, a annoncé de nouvelles primes d'incitation pour les employés. Le 7 août 2024, le Comité de Rémunération de l'entreprise a accordé des attributions d'unités d'actions restreintes couvrant 10 199 actions ordinaires de Nevro à quatre nouveaux employés non exécutifs. Ces attributions, accordées dans le cadre du Plan d'Attributions d'Incitation Nevro Corp. 2023, sont conçues pour inciter les nouvelles recrues et seront acquises sur une période de trois ans, sous réserve d'un emploi continu. Les attributions sont conformes à la Règle 303A.08 du Manuel des Sociétés Cotées de la NYSE, qui permet des attributions d'incitation pour attirer de nouveaux talents. Nevro a également souligné sa pratique d'affichage d'informations importantes pour les investisseurs sur son site Web.
Nevro Corp. (NYSE: NVRO), ein globales Medizintechnikunternehmen, das sich auf Lösungen zur Behandlung chronischer Schmerzen spezialisiert hat, hat neue Anreizvergaben für Mitarbeiter bekannt gegeben. Am 7. August 2024 vergab der Vergütungsausschuss des Unternehmens eingeschränkte Aktienoptionspreise, die 10.199 Aktien von Nevro abdecken, an vier neue nicht-executive Mitarbeiter. Diese Preise, die im Rahmen des Nevro Corp. 2023 Anreizvergabplans vergeben werden, sollen neue Einstellungen anspornen und werden über einen Zeitraum von drei Jahren aktiviert, sofern die Beschäftigung fortgesetzt wird. Die Vergaben entsprechen der Regel 303A.08 des NYSE Unternehmenshandbuchs, die Anreizvergaben zur Anwerbung neuer Talente erlaubt. Nevro betonte auch seine Praxis, wichtige Informationen für Investoren auf seiner Website zu veröffentlichen.
- Attraction of new talent through stock-based compensation
- Compliance with NYSE regulations for inducement awards
- Potential dilution of existing shareholders' stock value
Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in
Nevro recently added a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI joint") pain and now provides the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.
Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302222721.html
SOURCE Nevro Corp.
FAQ
What type of inducement grants did Nevro (NVRO) announce on August 14, 2024?
How do the inducement grants for Nevro (NVRO) employees vest?
Under which plan were Nevro's (NVRO) new employee inducement grants awarded?
What NYSE rule does Nevro's (NVRO) inducement grant comply with?
